Mebendazole polymorph C for the treatment of brain tumors - what does US patent US 11,110,079 B2 really protect? The US patent US 11,110,079 B2 (granted on September 7, 2021) describes a very specific „repurposing“ approach: The known anthelmintic active ingredient mebendazole is not simply to be used „off-label“, but in a defined crystal form (polymorph C) and in a specific galenic formulation.Continue reading